PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

May 24, 2017

byncaipen

Ophthalmology | Transplants

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP®

About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the...Read more

Feb 07, 2017

byncaipen

Ophthalmology

ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration

St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.